Savara (NASDAQ:SVRA) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Savara (NASDAQ:SVRA) in a research note published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $8.00 target price on the stock.

A number of other equities research analysts have also commented on the company. HC Wainwright lowered their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Evercore ISI reiterated an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.86.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.23 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a 50-day moving average price of $3.47 and a 200-day moving average price of $3.98. The stock has a market capitalization of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. Savara has a 1 year low of $2.82 and a 1 year high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, equities research analysts forecast that Savara will post -0.45 EPS for the current fiscal year.

Insider Activity at Savara

In related news, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.

Institutional Trading of Savara

Several hedge funds have recently made changes to their positions in SVRA. Frazier Life Sciences Management L.P. increased its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after acquiring an additional 4,157,385 shares during the last quarter. Nantahala Capital Management LLC boosted its position in Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after purchasing an additional 3,443,541 shares during the period. Farallon Capital Management LLC increased its stake in shares of Savara by 90.5% in the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after purchasing an additional 2,165,701 shares in the last quarter. First Light Asset Management LLC bought a new stake in shares of Savara in the second quarter valued at approximately $8,069,000. Finally, Wellington Management Group LLP lifted its stake in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after buying an additional 1,608,522 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.